Betaglue
2 known investors
BetaGlue Therapeutics develops targeted nuclear radiotherapeutics for solid tumours, combining biotechnology, nuclear science, and interventional oncology to deliver radiation inside the tumour. Its product, YntraDose, is a Yttrium-90 microsphere radiotherapy aimed at treating pancreatic cancer and other solid tumours.